Aquestive Therapeutics (AQST) Change in Receivables (2017 - 2026)

Aquestive Therapeutics' Change in Receivables history runs 10 years deep, the most recent figure standing at -$10.9 million for Q1 2026.

• On a quarterly basis, Change in Receivables fell 448.23% year-over-year to -$10.9 million in Q1 2026; TTM through Mar 2026 was -$3.7 million, a 267.42% decrease from a year earlier, with the FY2025 full-year figure at $10.4 million, up 1048.08% from the prior year.
• Change in Receivables eased to -$10.9 million in Q1 2026 per AQST's latest filing, from $6.0 million in the prior quarter.
• Across five years, Change in Receivables topped out at $7.7 million in Q1 2022 and bottomed at -$10.9 million in Q1 2026.
• The 5-year median for Change in Receivables is -$104000.0 (2023), against an average of -$346882.4.
• Across the five-year window, Change in Receivables tumbled 2132.69% in 2024 and jumped 2228.57% in 2025, its largest moves.
• Year by year, Change in Receivables stood at -$6.1 million in 2022, then soared by 98.29% to -$104000.0 in 2023, then tumbled by 2132.69% to -$2.3 million in 2024, then soared by 356.63% to $6.0 million in 2025, then sank by 282.85% to -$10.9 million in 2026.
• Per Business Quant, the three latest AQST Change in Receivables figures stand at -$10.9 million (Q1 2026), $6.0 million (Q4 2025), and -$63000.0 (Q3 2025).